FDA Premarket Activity Safe From Current Political Storm – Ex Chief Counsel
This article was originally published in The Gray Sheet
Executive Summary
Current public pressure on the FDA in the wake of a string of high-profile safety problems for both drugs and devices will not make the agency more restrained in approving premarket applications, according to one former top FDA official
You may also be interested in...
Collaboration With Industry And CMS Are Priorities For FDA’s Gottlieb
The pressure of meeting MDUFMA premarket review deadlines has prevented FDA reviewers from having "as much interaction as they would like with companies," according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting
CDRH 2006 Priorities Reflect Urgency Of Device Postmarket Issues
CDRH's fiscal year 2006 priorities highlight the pressing need to address postmarket device safety concerns following the string of cardiac rhythm management product recalls this summer